Atrial Fibrillation
Conditions
Keywords
Atrial fibrillation, anticoagulant treatment, apixaban, dabigatran, rivaroxaban, vitamin K antagonist, stroke prevention
Brief summary
Evaluation of clinical characteristics and pharmacotherapy of hospitalized Polish patients with atrial fibrillation (AF).
Detailed description
Atrial fibrillation (AF) is a common arrhythmia associated with increased cardiovascular mortality. An important element of management of patients with AF is anticoagulation to prevent thromboembolic events. Non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) are two main drugs groups used in thromboembolic events prevention. Primary objective of the study is to assess the frequency of VKAs vs NOACs prescription in AF patients treatment of with OACs. Secondary objective of the study are as follows: assessment of the frequency of appropriate/inappropriate OACs prescription in AF patients and assesment of the number of patients with AF treated with apixaban, dabigatran and rivaroxaban with high thromboembolism risk according to CHA2DS2-VASc score. The POL-AF Registry is a multicenter prospective analysis of hospital records of patients with AF managed in ten cardiology centers. Collected data will include demographics, type of AF (valvular and non-valvular, as well as paroxysmal, persistent and permanent), medical history, laboratory tests, echocardiographic parameters and concomitant medications. Each patient will be evaluated regarding to common scales assessing risk of thromboembolic (CHA2DS2-VASc) and bleeding (HAS-BLED, modifiable and non-modifiable risk factors for bleeding in anticoagulated patients basing on the current guidelines for AF treatment) events.
Interventions
OTHERobservation
observation
Sponsors
Medical University of Warsaw
Jan Kochanowski University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- patients with AF hospitalized in a participating center during study period
Exclusion criteria
* hospitalisation for atrial fibrillation ablation * death during hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the frequency of VKAs vs NOACs prescription in AF patients treatment of with OACs. | Through the study completion, an average of 2 months. | Compared data will include: frequency of VKAs vs NOACs prescriptions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the frequency of appropriate/inappropriate OACs prescription in AF patients. | Through the study completion, an average of 2 months. | Compared data will include: demographics, type of AF, medical history, baseline characteristics and concomitant medications. |
| Number of patients with AF treated with apixaban, dabigatran and rivaroxaban with high thromboembolism risk according to CHA2DS2-VASc (heart failure, hypertension, age, diabetes mellitus, stroke/TIA/thromboembolism, vascular disease and sex) score. | Through the study completion, an average of 2 months. | The CHA2DS2-VAS score includes the following factors: heart failure, hypertension, age, diabetes mellitus, stroke/TIA/thromboembolism, vascular disease and sex. According to the CHA2DS2-VAS score, high thromboembolic risk means 2 points in men, 3 points in women. Data on the components of CHA2DS2-VASC are obtained from medical records. |
Countries
Poland
Outcome results
None listed